As part of the MDS+AML MATTER program, four live summits will be held in cities across the U.S., with opportunities to earn up to 6.0 CME credits/CNE contact hours. There is no fee to register, and all health care professionals involved in the diagnosis and management of patients with MDS or AML are encouraged to attend.

Prior to the summit, participants will engage in pre-meeting learning. Educational materials will include the relevant guidelines for both MDS and AML diagnosis and treatment as well as informative articles on those topics.

Dates and Locations

To view additional summit details, please click the links below for each location.


September 6, 2018

Chicago, IL

Learn more


October 19, 2018

Washington, DC

Learn more


January 10, 2019

San Francisco, CA

Learn more


January 24, 2019

New York, NY

Learn More


Please see the individual summit page to confirm start and end times in that location.

15 minutes Welcome, Introductions, and Summit Overview
1 hour, 30 minutes Tumor Board Presentation of MDS and AML
Faculty will identify a clinical case in which MDS transforms into AML and will lead a discussion on the case using a tumor board format. After the case discussion, faculty will review optimal diagnostic and treatment choices.
15 minutes Break
2 hours Breakout Sessions
Participants will rotate through four 30-minute breakout sessions on the following topics:
  • Diagnosis of myeloid neoplasms, including morphology, cytogenetic, and molecular testing
  • Treatment decision-making/management for MDS
  • Treatment decision-making/management for AML
  • The role of minimal residual disease and transplant in MDS and AML
Discussions will focus on bone marrow specimen retrieval and preparation, testing algorithms, interpretation of testing results, classification and risk stratification of both MDS and AML, optimal timing for a referral to hematopoietic cell transplantation, and other considerations for eligibility for HCT.
30 minutes Lunch (featuring The Patient Voice)
To incorporate the patient/caregiver perspective, during lunch participants will hear from an MDS and/or AML patient. The patient video will share stories to create the framework and context on issues that are most important to them (e.g., educational needs and psychosocial challenges).
1 hour Practice-Based Learning
Participants will be assigned to small workgroups. Each group will work as a team in the time allotted to discuss clinical evaluation, testing needed to narrow the differential diagnosis, bone marrow specimens, and treatment plans as applicable to their role in the diagnosis, evaluation, and management of patients with AML.
1 hour Workgroup Presentations and Q&A
Each workgroup will present its patient care plan to the audience for feedback and discussion. Faculty will assess and evaluate each group’s presentation.
15 minutes Learners Discuss Key Takeaways and Develop Action Plans
Participants will revisit the key challenges identified at the beginning of the program, discuss what they have learned, and develop an action plan for incorporating the new knowledge and competence into practice.
15 minutes Post-Activity Survey, Evaluations, and Summit Wrap-Up

Continuing Education Credit Designations

For Physicians

The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

ASH designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses

The Oncology Nursing Society is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850. This activity is awarded 6.0 contact hours of continuing nursing education for RNs.

back to top